Direct answer

Jaipur-based healthtech startup Aignosis has raised ₹4 crore in a seed round led by Antler and Nikhil Kamath, with participation from Varun Dua and IIMA Ventures.

The round was reported by ETEntrepreneur on 1 October 2026. Aignosis plans to use the capital to expand its AI-assisted autism and developmental screening platform through public and private healthcare networks. The Best CS Firm In India fundraising lesson is that healthtech diligence must connect product claims to regulatory status, clinical evidence, data governance and a realistic care pathway.

Funding snapshot

What the startup does

Aignosis offers an initial screening layer for children aged 16 months to nine years. Its system uses a standard laptop and webcam, presents nine stimulus modules and applies computer vision to behavioural signals such as gaze, response to name and reactions to facial expressions.

The output is a risk report indicating whether formal clinical assessment may be warranted. This boundary matters: the product is presented as screening support, not an autonomous diagnosis. ETEntrepreneur reports that the company has completed the CDSCO regulatory process and received Class B certification for the screening technology.

Traction and planned expansion

• More than 8,000 screenings completed, according to the company.
• Deployment across more than 20 government primary health centres in Rajasthan.
• A reported partnership with Mankind Pharma’s field network for paediatric screening camps.
• Operations beginning with Apollo Shines across around 125 schools.
• A target of at least 100,000 screenings by the end of FY27.
• Planned expansion into Punjab, NCR, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra.

These operating and target figures are company-reported and should be tested during diligence rather than treated as audited facts.

Why investors may have funded Aignosis

Analysis and inference: no investor has published a complete investment memorandum. Based on the disclosed facts, the likely attractions include a large under-screened need, a low-hardware deployment model, regulatory progress, institutional distribution and a clear referral role rather than an overbroad diagnostic claim.

Three-year outlook

Reasoned forecast, not a company promise:

• Year 1: state-by-state deployment, clinical workflow standardisation, hiring and evidence generation are likely priorities.
• Year 2: Aignosis may deepen hospital, school and public-health partnerships while improving referral and follow-up analytics.
• Year 3: the company could pursue broader developmental-screening modules or selected international markets, but only if regulatory, clinical and privacy evidence scales with product claims.

The main execution risks are false-positive or false-negative performance, inconsistent operator conditions, child-data safeguards, institutional sales cycles, clinician adoption and maintaining regulatory alignment as the model changes.

How similar founders can approach these investors

1. Antler: use its official India application or direct-outreach route with a concise problem, founder advantage, early evidence and why AI is essential.
2. IIMA Ventures: map the company to its incubation or investment themes and provide validation milestones, regulatory plan and measurable impact.
3. Strategic angels: seek a warm introduction from a relevant operator, clinician, founder or existing investor.
4. Lead with evidence: present labelled retrospective data, prospective validation plans and deployment economics—not only model accuracy.
5. Prepare the round: define amount, runway, milestone plan, governance asks and the next institutional financing proof points.

Investor data-room checklist for healthtech AI

• Certificate of incorporation, constitutional documents, statutory registers and ROC filings.
• Cap table, securities history, shareholder agreements, ESOP pool and option grants.
• Board and shareholder approvals for prior issuances, related-party transactions and the new round.
• FEMA documents for any non-resident investment, including valuation and reporting records.
• CDSCO applications, licences or certificates, intended-use statement and change-control history.
• Clinical evaluation protocol, study reports, performance limitations and adverse-event process.
• DPDP-ready privacy notices, consent records, child-data safeguards, processor contracts and retention schedule.
• Cybersecurity architecture, access logs, incident plan, penetration tests and cloud agreements.
• Founder, employee and contractor IP assignments; patent and trademark records.
• Hospital, government, pharma, school and channel agreements with responsibility allocation.
• Revenue, deployment, screening and referral metrics reconciled to source systems.
• GST, tax, payroll, labour, insurance and material-litigation records.

Cap-table and term-sheet controls

• Reconcile the fully diluted cap table to every executed instrument.
• Model the seed round and ESOP pool on a pre- and post-money basis.
• Identify liquidation preference, anti-dilution, information and reserved-matter rights.
• Check founder vesting, good-leaver and bad-leaver clauses against employment terms.
• Keep product or clinical milestones separate from vague discretionary investor tests.
• Confirm that regulatory representations are accurate and appropriately qualified.

Mistakes similar founders should avoid

• Calling a screening output a diagnosis in marketing or fundraising.
• Using child data without clear purpose, consent, access and retention controls.
• Quoting pilots as recurring revenue without labelling them.
• Presenting model accuracy without population, sample size and limitations.
• Leaving hospital, school or government responsibilities undefined.
• Approaching investors before reconciling the cap table and regulatory file.

Founder / Business Takeaway

Aignosis demonstrates that a healthtech fundraising story becomes stronger when technology, regulatory status, clinical boundaries and distribution reinforce one another. Similar founders should make every traction claim traceable and every product claim consistent with the approved intended use.

Suggested internal links

• Investor due-diligence checklist
• Startup cap-table checklist
• BSA Daily Funding Alerts

FAQ

How much did Aignosis raise?

The startup raised ₹4 crore in a seed round announced on 1 October 2026.

Who invested?

Reported investors are Antler, Nikhil Kamath, Varun Dua and IIMA Ventures.

Is the product a diagnosis?

No. The reported product is an initial screening layer that generates a risk report to support referral for formal clinical assessment.